Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants With Moderate to Severe Atopic Dermatitis.

NCT06447506 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT06447506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06447506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants With Moderate to Severe Atopic Dermatitis.
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Terminated
Start date
June 5, 2024
Completion date
July 29, 2025
Enrollment
79 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis, atopic